Plain-English translation of NCT06017284 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called can help reduce the side effects of chemotherapy for people with advanced pancreatic cancer. You would take as a pill once a day while receiving your regular chemotherapy treatment. The study wants to see if this medication can reduce nausea and vomiting, help you sleep better, and improve your overall quality of life.
Standard chemotherapy for advanced pancreatic cancer is effective, but it often causes severe nausea, vomiting, poor sleep, and fatigue that make it hard for patients to tolerate treatment. This trial is exploring whether this medication—which works by reducing inflammation in the body—might ease these side effects and help patients stay on their cancer treatment longer.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy infusions on specific days (days 1, 8, and 15 of each 4-week cycle), plus a daily pill to take at home each evening. You'll also have check-in visits every 4 weeks where your doctors measure nausea levels, sleep quality, pain, and overall quality of life. The study involves 100 patients total—some will receive the new medication alongside chemotherapy, and others will receive chemotherapy with a placebo pill, assigned randomly.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Fudan University
Enrollment target
~100 participants
Started
November 2023
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in November 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ying Yang, MD
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.